Investment Research Radio

BiRed Imaging founders discuss infrared breast cancer screening tech, FDA path, and clinical results

19 min Listen to the original Episode page
OncologyMedical DevicesFDA RegulationInfrared ImagingDiagnostics

Summary

Dr. Satish Kandlikar and Dr. Prad Phatak of BiRed Imaging explain their infrared-based breast cancer screening technology, which uses inverse heat transfer modeling to detect tumors without radiation or compression. They cite clinical studies showing 100% sensitivity in small cohorts, aiming to address the limitations of mammography in dense breast tissue. The company is pursuing dual FDA regulatory clearance, targeting hardware clearance and software approval, with larger trials planned for 2027. They position the device as complementary to existing methods, potentially reducing unnecessary biopsies.

Episode sections

  1. 0:26 – 1:17

    Introduction and Company Background

    Host Ray Crowley introduces CEO Satish Kandlikar and CMO Dr. Pradyumna Phatak. Kandlikar shares his academic background and personal motivation from his wife's false-positive mammogram.

  2. 1:17 – 4:39

    Technology Development and Scientific Basis

    Kandlikar explains the history of infrared imaging since 1986 and the partnership with Phatak to develop a mathematically rigorous inverse heat transfer simulation method.

  3. 4:39 – 7:11

    Clinical Problem and Solution Mechanics

    Dr. Phatak discusses the ~40% of women with dense breasts and how BiRed's system uses infrared cameras and software to locate metabolically active tumors.

  4. 7:11 – 9:54

    User Experience and Device Operation

    Description of the prone exam table with infrared cameras below, emphasizing the non-invasive, radiation-free nature of the exam.

  5. 9:54 – 12:22

    Clinical Study Results and Validation

    Review of 2020 studies showing 100% sensitivity/specificity and 2024-2025 Rochester General Hospital studies with ~30 patients maintaining 100% sensitivity.

  6. 12:22 – 14:06

    Regulatory Strategy and Milestones

    Outline of the dual FDA path (510(k) for hardware, accelerated approval for software) and plans for two hospital devices by 2027.

  7. 14:06 – 15:04

    Market Size and Vision

    Discussion of the addressable market, aiming to reduce 450,000 unnecessary biopsies annually, and positioning as complementary to mammography.

  8. 15:04 – 19:01

    Future Outlook and Contact

    Targeting FDA approval by 2028, contingent on 2027 trial enrollment and funding. Website bireadimaging.com mentioned for updates.

Claims worth verifying

BiRed Imaging is a private venture in the world of oncology.

Unidentified speaker (speaker_1) ·0:44

How to verify: Check corporate registry filings for BiRed Imaging's legal status and ownership structure. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Primary source

Satish Kandlikar is a Gleason professor of mechanical engineering and distinguished institute professor at Rochester Institute of Technology.

Professor Satish Kandlikar ·1:17

How to verify: Search the Rochester Institute of Technology faculty directory or official university press releases for his title and appointment. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Infrared imaging for breast cancer detection started in 1986.

Professor Satish Kandlikar ·3:20

How to verify: Search academic databases (PubMed, IEEE Xplore) for literature on infrared thermography in breast cancer dating back to 1986. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Approximately 40% of women who get screened have dense breasts.

Professor Satish Kandlikar ·5:50

How to verify: Review CDC or American Cancer Society statistics on breast density prevalence in screening populations. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

BiRed was founded in 2020.

Unidentified speaker (speaker_3) ·9:20

How to verify: Check the 'About Us' section of bireadimaging.com or SEC EDGAR filings if any public disclosures exist. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Primary source

Initial clinical studies in 2020 showed 100% sensitivity and 100% specificity.

Professor Satish Kandlikar ·10:41

How to verify: Search for published clinical trial results or conference abstracts from 2026-2026 detailing BiRed's initial patient cohort outcomes. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Clinical studies restarted in 2024-2025 at Rochester General Hospital with ~30 patients.

Unidentified speaker (UNKNOWN) ·10:56

How to verify: Check clinical trial registries (ClinicalTrials.gov) for BiRed Imaging studies at Rochester General Hospital with enrollment dates in 2026-2026. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

The system is 100% sensitive in recent studies, missing no cancers.

Professor Satish Kandlikar ·11:17

How to verify: Review the published or presented data from the 2026-2026 Rochester General Hospital study cohort. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

There are close to 450,000 unnecessary biopsies performed through the mammography paradigm annually.

Unidentified speaker (speaker_3) ·17:50

How to verify: Search medical literature or health economics reports for statistics on false-positive mammogram rates and subsequent biopsy volumes. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

The company plans to place two FDA-standard devices in two hospitals by the beginning of next year (2027).

Unidentified speaker (UNKNOWN) ·12:21

How to verify: Monitor BiRed Imaging press releases or hospital partnership announcements for device installation dates in 2026. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify the 100% sensitivity/specificity claims by reviewing the full peer-reviewed publications from the 2020 and 2024-2025 studies.
  • Check the FDA 510(k) database for any existing cleared devices similar to BiRed's hardware.
  • Review BiRed Imaging's patent portfolio to confirm IP ownership and freedom to operate.
  • Assess the sample size limitations of the cited clinical studies (e.g., ~30 patients) versus standard regulatory requirements.
  • Investigate the competitive landscape of non-radiation breast cancer screening technologies.
  • Confirm the timeline for the 2027 hospital placements and larger clinical trials.
  • Look for conflicts of interest or funding sources disclosed in the cited clinical studies.
Full transcriptexpand
0:00
Ray Crowley: You are now dialed into Investment Research Radio. All material on this program is not to be taken as investment advice and is for informational purposes only. Investment Research Radio interviews the most exciting up-and-coming companies as well as market commentary from leading
0:20
Ray Crowley: analysts and traders. Now with your host, Ray Crowley.
0:26
Unidentified speaker (speaker_1): Welcome to Investment Research Radio. I'm your host, Ray Crowley, and today we're joined by Professor Satish Kandlicar, CEO and co founder,
0:39
Unidentified speaker (speaker_1): and also
0:40
Unidentified speaker (speaker_1): Dr. Pratt Patak,
0:44
Unidentified speaker (speaker_1): who is CMO and co-founder. co founder. And this company is BiRed Imaging, which is a private venture in the world of uh in the world of oncology. Thanks for joining us, uh gentlemen.
0:59
Professor Satish Kandlikar: Thank you. Thank you all.
1:02
Unidentified speaker (speaker_1): So we'll I guess we'll start with uh with Satish.
1:06
Unidentified speaker (speaker_1): Tell us uh a bit about the briefly um your backgrounds and um
1:13
Unidentified speaker (UNKNOWN): what
1:13
Unidentified speaker (speaker_1): prompted you to start. this company.
1:17
Professor Satish Kandlikar: I'm uh I'm Satish Kandlighar. I am a Gleason professor of mechanical engineering and also a distinguished institute professor at Rochester Institute of Technology. And my focus is mainly research in the area of heat transfer. Uh there
1:37
Professor Satish Kandlikar: are two reasons behind. behind why we started this venture. One is very personal.
1:45
Professor Satish Kandlikar: It was uh many years ago and I was going to Japan and uh just a day before or two days before my wife went for mammography and she was recalled and they said they need to do biopsy.
2:04
Unidentified speaker (UNKNOWN): I
2:05
Professor Satish Kandlikar: had to go to Japan and she was going to go through a biopsy, and I could not change my schedule. And I saw that this uh event is kind of replicated in many households.
2:25
Professor Satish Kandlikar: And when we found the results, there was no cancer, so everything was fine. We were very fortunate. But the pain, the agony that you go through these false alarms is huge. And as Dr. Patak will tell you, that all these
2:45
Professor Satish Kandlikar: false positives are many of them lead to biopsy. And that is a very personal thing affecting millions of women and their families. The second reason is from my background. I'm a heat transfer person, and in
3:04
Professor Satish Kandlikar: 2014,
3:06
Professor Satish Kandlikar: we
3:07
Professor Satish Kandlikar: had a high resolution infrared camera in our lab, and uh we were brain. brainstorming what we could do. And uh at that time
3:20
Professor Satish Kandlikar: we saw breast cancer detection with infrared uh uh uh imaging coming up uh around the world. It was it was started in 1986, but it kind of was not standardized. and mammography
3:40
Professor Satish Kandlikar: was uh the chosen one, and it was uh enhanced with research of many years. So
3:50
Professor Satish Kandlikar: in thermography, they just look at images of temperature patterns, uh, thermal patterns, and make a prediction. So it's not science science-based. based, and I'm an analytic. analytical, uh, I'm a person with analytical background, and I thought we could do something better. And that's
4:09
Professor Satish Kandlikar: where uh uh uh Dr. Patak and I, we worked together, uh our close friends, and we just did a brainstorming, and Dr. Patak will tell you his perspective how things went from there.
4:27
Unidentified speaker (speaker_1): Yeah, sure. Uh Dr.
4:32
Unidentified speaker (speaker_1): Tell us about the um the the problems that you've seen that this could solve and what you're working
4:38
Unidentified speaker (UNKNOWN): on.
4:39
Professor Satish Kandlikar: Yeah, thank you. Um so I am a cancer specialist by training, uh A hematology oncology physician. So uh breast cancer is certainly in my world. And unfortunately, once cancer spreads outside the breast, we can do all kinds
4:59
Professor Satish Kandlikar: of things to control it, but curing it is very, very difficult. So our best weapon in the war against breast cancer, if you will, is to screen for it and find it early. So this has been going on. like Satish said, since the 70s and 80s.
5:18
Professor Satish Kandlikar: Mammography has been studied, thermography was looked at, and mammography was sort of the chosen one, but it's just not a great technique. It screens for breast cancer, it finds breast cancer early, and it's the recommended thing to do. But
5:35
Professor Satish Kandlikar: finds many people with lesions that are benign, don't really need to be found. It also misses some cancers because some women have dense breasts.
5:50
Professor Satish Kandlikar: It's estimated about 40% of women who get screened have something called dense breasts, which is radiographic density, uh, makes the breast cancer difficult. for the radiologist to see.
6:05
Unidentified speaker (UNKNOWN): So
6:05
Professor Satish Kandlikar: mammography both misses cancers and finds too many other lesions. So we need a better technique. It's been known for some time that cancers generate heat. So this idea of using heat and temperature always appealed to me a little bit. And with Satisha's expertise, it became
6:25
Professor Satish Kandlikar: possible to really do this. in a scientific way. Look at surface temperature profiles, back calculate where the heat source must be in order to generate
6:36
Unidentified speaker (UNKNOWN): that
6:37
Professor Satish Kandlikar: temperature profile. And so we thought, gee, this is something we ought to study. This is not thermography. It's a new and different way of looking at temperatures. And so that's what got us interested in this. Mostly Satisha's brainchild and he had all the equipment.
6:53
Unidentified speaker (UNKNOWN): Uh
6:53
Professor Satish Kandlikar: I provided the clinical perspective.
6:56
Unidentified speaker (speaker_1): Excellent. Could you uh walk us through or one of you walk us through the uh the user experience? Uh what does it look like and and why is it better than what's out there now?
7:11
Professor Satish Kandlikar: Sure, it's it's it's a very easy technique. So what we have is like a simple exam table with a hole in it. The woman lies prone with one breast hanging through the hole. We have cameras below that measure surface
7:31
Professor Satish Kandlikar: temperature um at thousands of points on the breast and collect this data
7:38
Unidentified speaker (UNKNOWN): and
7:38
Professor Satish Kandlikar: then we have computers and software that analyzes it, which Satish can speak to better than I can, and predicts whether there's a cancer or not and where that cancer is located. So it's very simple. It's no touch, it doesn't compress the breast like mammography
7:58
Professor Satish Kandlikar: does. There's no radiation, there's no contrast involved. um, relatively inexpensive equipment, um,
8:07
Unidentified speaker (UNKNOWN): and
8:07
Professor Satish Kandlikar: great results, as we'll tell you in a
8:10
Unidentified speaker (UNKNOWN): moment.
8:12
Unidentified speaker (speaker_3): Yeah.
8:14
Unidentified speaker (speaker_3): What we do is basically take all the data, reconstruct the breast digitally, and we know all the
8:27
Unidentified speaker (speaker_3): temperatures at all the surface points on the breast. We know the temperatures, we know the temperature of the patient.
8:37
Unidentified speaker (speaker_3): So we have to find out what is in there that gives this particular temperature uh pattern
8:47
Unidentified speaker (speaker_3): or temperature data on the breast surface. So we detect the metabolically active tumor within the breast, and our software backcalculates by placing that tumor different places and then zeros down on a
9:07
Unidentified speaker (speaker_3): specific location and its diameter. So that's a uh unique uh inverse modeling concept. that we utilize and uh uh
9:20
Unidentified speaker (speaker_3): the system has been uh tested we found were founded in 2020 before that we had an NSF project in 2016 i graduated three PhD students the software was developed and we started the company in 2020
9:40
Unidentified speaker (speaker_3): after acquiring the patents, and we generated our own patents since then.
9:47
Unidentified speaker (speaker_1): Excellent. So, how far along are you in terms of the development of the technology?
9:54
Unidentified speaker (speaker_3): Right now, I think before we go into that, our clinical studies are very impressive. And Dr. Patak can highlight some of the results from our clinical study.
10:09
Professor Satish Kandlikar: Sure. So we did our initial clinical study in 2020. So this was just a concept before that, between 2016 and 2020.
10:21
Professor Satish Kandlikar: The results of that just blew us away. It was a small number of patients. all of whom had a cancer. So we were starting out with known cancer patients. Uh, but the other side, the normal side, served as some normal control. So we were uh looking at some normal breasts as well. And it was a
10:41
Professor Satish Kandlikar: hundred percent sensitive and a hundred percent specific. Nothing in medicine is is like that. So that kind of blew us away. Then during the pandemic, we had to slow down. a little bit because clinical research like that was difficult to do. And
10:56
Unidentified speaker (UNKNOWN): Dr.
10:57
Professor Satish Kandlikar: Kandlicker and his team worked on the software, made it a little more usable. And then 24-25, we were able to restart clinical studies, place the device at Rochester Mr. General. And once again, we have data on it's not a huge number, about 30. patients. This time
11:17
Professor Satish Kandlikar: we're uh enrolling both people with cancers and other people who get flagged by mammography. So far, again, have not missed a single cancer, so it's 100% sensitive. Um it um picks up an occasional benign lesion uh as a heat source, so there there are some false
11:37
Professor Satish Kandlikar: positives, uh, but nowhere near what mammography sees. So we think adding this on
11:44
Professor Satish Kandlikar: will detect more cancers and will also save some people from unnecessary biopsies. It's not affected by breast density because the heat signal has nothing to do with radiographic density. Uh so we can detect in
12:04
Professor Satish Kandlikar: anybody. And so that's where we're at at this point. We're manufacturing two devices that will be built by FDA standards, placed at two different hospitals by the beginning of next year, and we're starting bigger clinical studies, which we're extremely excited
12:21
Unidentified speaker (UNKNOWN): about.
12:22
Unidentified speaker (speaker_1): Tell us about the uh regulatory journey, uh how how that's been so far and how you see that coming through.
12:30
Professor Satish Kandlikar: Yeah. So we have utilized a consultant for that who's done uh regulatory for medical devices in the past. Um and the strategy is sort of twofold. So, as I said, we're measuring temperature, which is similar to prior thermography. So the hardware um
12:51
Unidentified speaker (UNKNOWN): uh
12:51
Professor Satish Kandlikar: we're looking for 510k fda approval for which we're hoping might be easy but then we're also looking for accelerated approval as a screening device the combination of hardware and software i imagine that's going to take a little more
13:11
Professor Satish Kandlikar: data and so we're it's it's a dual approach
13:15
Professor Satish Kandlikar: Um and we think is very viable.
13:19
Unidentified speaker (UNKNOWN): Do
13:19
Unidentified speaker (speaker_1): you see this as a a replacement for mammography or more of a complementary um
13:26
Professor Satish Kandlikar: tool? So um at this point we're we're thinking complementary. Uh we don't have enough data to say this is gonna going to stand by itself. Uh so we're gonna going to introduce it as a as an adjunct to mammography. If mammography is positive, um, you know, you can do this and and
13:46
Professor Satish Kandlikar: prevent unnecessary biopsy. Eventually we think pairing it with mammography so we can find some cancers that mammography doesn't detect.
13:56
Unidentified speaker (UNKNOWN): And
13:56
Professor Satish Kandlikar: then eventually, who knows, as the data matures, this might turn out to be a better technique. But that's
14:03
Professor Satish Kandlikar: way in the future.
14:06
Unidentified speaker (speaker_1): So
14:07
Unidentified speaker (speaker_1): this, I mean, obviously, breast cancer is quite a unfortunately common cancer. So I'm I'm assuming that this is quite a large market.
14:18
Professor Satish Kandlikar: Yes, it's a huge market. So breast cancer, one in six women will get breast cancer at some point during their life. The recommendation is that everybody start getting screened for breast cancer. Some people say at age 40, some people say at age 50. Women at high genetic risk should be screened even earlier, starting at
14:38
Professor Satish Kandlikar: 20, 25.
14:40
Professor Satish Kandlikar: So there are lots of screenings that happen. And if we can make that screening better and easier, women are will be more. likely to participate in screening programs. And I think we'll detect more breast cancers and accurately find cancer
15:00
Professor Satish Kandlikar: rather than finding benign lesions.
15:04
Unidentified speaker (UNKNOWN): So
15:04
Unidentified speaker (speaker_1): what are the you mentioned getting set up with two machines into hospitals Uh in the near future? Over the next one to two years, what are the major milestones that you're looking to accomplish?
15:19
Unidentified speaker (UNKNOWN): So
15:19
Unidentified speaker (speaker_3): we're
15:21
Unidentified speaker (speaker_3): in Dr. Pina.
15:23
Professor Satish Kandlikar: So we're planning to start uh clinical trials. Um
15:27
Unidentified speaker (UNKNOWN): at
15:28
Professor Satish Kandlikar: uh so we'll we'll open a trial that will uh enroll patients at both of these sites. Uh the goal is to get enough data for FDA approval. And in the meantime, we'll start our submissions to the FDA, both for the 510K and the accelerated approval that I
15:48
Professor Satish Kandlikar: talked about before. They will guide us as to how many patients and how long that's going to take. Obviously, funding is is a a barrier. We're looking for grant support for that. We're also looking for investor support. for that.
16:04
Professor Satish Kandlikar: And uh we hope to enroll a significant number of patients in 2027. So by 2028, we're targeting some kind of FDA approval and then much bigger expansion from there on.
16:22
Unidentified speaker (speaker_1): Before we wrap things up, uh perhaps Satish Professor Satish.
16:27
Unidentified speaker (speaker_1): could uh tell us uh the the big vision for the company.
16:33
Unidentified speaker (speaker_3): Yeah, I think the big vision has to do with everybody, everybody's sufferings. We can elevate some of that by providing a radiation-free, radiation free, compression-free compression free technique. to detect breast cancer. It
16:53
Unidentified speaker (speaker_3): also opens up another uh segment, as Dr. Patak said, women are screened beyond age 40 and those who are more genetically predisposed could be screened earlier. But the dilemma here is they have
17:13
Unidentified speaker (speaker_3): a radiation exposure which they really don't want. So this technique is radiation free. So that's another segment which could be addressed. Our big vision really is to help people
17:30
Unidentified speaker (speaker_3): find cancers which are missed by a current paradigm and also to reduce the unnecessary biopsies. There are close to 450,000 unnecessary biopsies which are performed through a mammogram uh
17:50
Unidentified speaker (speaker_3): mammography uh paradigm. We can avoid that or at least reduce that significantly. So our big vision revolves around these facts.
18:03
Unidentified speaker (speaker_1): And how can people find out more information
18:07
Unidentified speaker (UNKNOWN): if
18:07
Unidentified speaker (speaker_1): they're interested in learning more?
18:11
Unidentified speaker (speaker_3): We have a website which they can go to. It is bireadimaging.com. And it is uh it will be updated once uh we get the FDA clearance and so on. Uh right now it's it has the basic elements, our technology, and
18:31
Unidentified speaker (speaker_3): how to connect with us. So that would be our primary outlet.
18:38
Unidentified speaker (speaker_1): Well, thank you both so much for coming on to the podcast today. We're really excited about this company and what its uh potential implications are in the this space and looking forward. to seeing you guys succeed in the future.
18:55
Unidentified speaker (speaker_3): Thank you. Thank you very much, Ray. Thank you, Ray.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights